IDH2 and acute myeloid leukemia: Studies to date have shown that the efficacy of enasidenib, a drug targeting mutations in the mitochondrial isocitrate dehydrogenase (IDH)2 gene, is limited to less than 13% of patients with IDH2 mutations, which only accounts for a subset of AML cases characterized by unrestricted cell proliferation [9,10].